Benjamin Shaker - 14 Feb 2023 Form 4 Insider Report for agilon health, inc. (AGL)

Role
Chief Markets Officer
Signature
/s/ Timothy Bensley, as Attorney-in-Fact
Issuer symbol
AGL
Transactions as of
14 Feb 2023
Transactions value $
-$1,677,035
Form type
4
Filing time
16 Feb 2023, 16:38:29 UTC
Previous filing
19 Jan 2023
Next filing
17 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGL Common Stock Options Exercise $91.2K +30.4K +118.66% $3.00* 56K 14 Feb 2023 Direct F1
transaction AGL Common Stock Options Exercise $19.6K +19.6K +34.97% $1.00* 75.6K 14 Feb 2023 Direct F1
transaction AGL Common Stock Sale -$1.15M -50K -66.12% $22.98 25.6K 14 Feb 2023 Direct F1, F2, F3
transaction AGL Common Stock Options Exercise $28.6K +28.6K +111.43% $1.00* 54.2K 15 Feb 2023 Direct F1
transaction AGL Common Stock Sale -$667K -28.6K -52.7% $23.37 25.6K 15 Feb 2023 Direct F1, F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGL Options (Right to buy) Options Exercise $0 -30.4K -100% $0.00* 0 14 Feb 2023 Common Stock 30.4K $3.00 Direct F5
transaction AGL Options (Right to buy) Options Exercise $0 -19.6K -19.59% $0.00 80.4K 14 Feb 2023 Common Stock 19.6K $1.00 Direct F6
transaction AGL Options (Right to buy) Options Exercise $0 -28.6K -35.51% $0.00 51.9K 15 Feb 2023 Common Stock 28.6K $1.00 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes restricted stock units.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $22.59 to $23.225, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $22.79 to $23.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5 These options were granted on December 30, 2016 and vested on September 14, 2021.
F6 These options were granted on April 27, 2017, and became fully vested as of January 12, 2021.